Shilpa Gupta, MD, Cleveland Clinic

Articles

Metastatic Urothelial Carcinoma: Number of Frontline Chemotherapy Cycles

May 4th 2023

A brief review of the appropriate number of chemotherapy cycles to utilize in the setting of metastatic urothelial carcinoma.

Dr Gupta on First-line Avelumab Maintenance in Advanced Urothelial Carcinoma

May 3rd 2023

Shilpa Gupta, MD, discusses findings from a long-term analysis of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

First-Line Treatment Options for Patients With Metastatic Urothelial Carcinoma

April 27th 2023

Switching their focus to the metastatic urothelial carcinoma treatment landscape, panelists identify cornerstone frontline treatment options.

Novel Treatment Strategies in Muscle Invasive Bladder Cancer

April 27th 2023

A comprehensive review of novel treatment strategies in MIBC, including perioperative therapy, and respective ongoing clinical trials.

Clinical Trial Data With Perioperative Therapy in MIBC: Bladder BRIDGister

April 20th 2023

Expert panelists reflect on the molecular subtyping of patients to predict response to neoadjuvant therapy in Bladder BRIDGister.

Clinical Trial Data With Perioperative Therapy in MIBC: HCRN GU 16-257

April 20th 2023

Shared insight on the combination of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer in the HCRN GU 16-257 trial.

Clinical Trial Data With Perioperative Therapy in MIBC: The RETAIN BLADDER Study

April 13th 2023

Focused discussion on the RETAIN BLADDER study, which explored the option to avoid cystectomy in patients with good response to systemic therapy.

Muscle-Invasive Bladder Cancer: Role of Minimal Residual Disease in Adjuvant Therapy

April 13th 2023

Continuing their discussion on adjuvant therapy in in muscle-invasive bladder cancer, panelists identify the utility of minimal residual disease testing.

Adjuvant Treatment Approaches in Muscle-Invasive Bladder Cancer

April 6th 2023

Centering discussion on several clinical trials, key opinion leaders reflect on the role of adjuvant therapy in muscle-invasive bladder cancer.

Evolving Neoadjuvant Treatment Strategies in Muscle-Invasive Bladder Cancer

April 6th 2023

Expert perspectives on the evolving role of neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) with considerations for mainstay regimens.

MIBC and mUC: Surgery, Systemic Therapy, and Bladder Preserving Treatments

March 30th 2023

Switching their focus to non-muscle-invasive bladder cancer (NMIBC), panelists identify the treatment armamentarium in this setting.

Novel Treatment Strategies in Non-Muscle Invasive Bladder Cancer

March 30th 2023

A bird’s eye view of treatment modalities in urothelial carcinoma covering systemic, surgical, and bladder preserving strategies.

How Many Lines of Therapy Are Patients Receiving for Urothelial Carcinoma?

March 23rd 2023

A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.

Overview of Practice Patterns in Urothelial Carcinoma

March 23rd 2023

A panel of four key opinion leaders share real-world urothelial carcinoma practice patterns at their respective institutions.

Dr. Gupta on the Investigation of Enfortumab Vedotin With or Without Additional Therapy in mUC

November 14th 2022

Shilpa Gupta, MD, discusses the investigation of enfortumab vedotin with or without additional therapy in cisplatin-ineligible metastatic urothelial carcinoma.

Dr. Gupta on Unmet Needs in Frontline Treatment of Metastatic Urothelial Cancer.

November 4th 2022

Shilpa Gupta, MD, discusses the unmet needs of patients with cisplatin-ineligible metastatic urothelial carcinoma.

Dr. Gupta on the Investigation of Cabozantinib Plus Avelumab in Metastatic Urothelial Cancer

October 18th 2022

Shilpa Gupta, MD, discusses the addition of cabozantinib to avelumab in locally advanced or metastatic urothelial cancer.

Dr. Gupta on the Results of the PARADIGM Study in Urothelial Cancer

June 28th 2022

Shilpa Gupta, MD, discusses the results of the PARADIGM study in locally advanced or metastatic urothelial cancer.

Dr. Gupta on the Methodologies of the PARADIGM Study in Urothelial Cancer

June 20th 2022

Shilpa Gupta, MD, discusses the methodologies utilized in the PARADIGM study in locally advanced or metastatic urothelial cancer.

Dr. Gupta on the Design of the PARADIGM Study in Urothelial Cancer

June 19th 2022

Shilpa Gupta, MD, discusses the design of the PARADIGM study in locally advanced or metastatic urothelial cancer.